| Gene symbol | CD59 | Synonyms | 16.3A5, 1F5, EJ16, EJ30, EL32, G344, HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, p18-20 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Description | CD59 molecule (CD59 blood group) | ||||
| GTO ID | GTC1922 |
| Trial ID | NCT03585556 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | CD59 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | HMR59 |
| Co-treatment | Oral prednisolone |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD) |
| Year | 2018 |
| Country | United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | 81201887MDG1002|HMR-1002|81201887MDG1002 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||